Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch & Lomb

This article was originally published in The Gray Sheet

Executive Summary

U.S. approval for the Keracor 116 excimer laser system for photorefractive keratectomy is announced Oct. 4. However, the company will forgo marketing and instead devote resources to the Technolas 217 for laser in situ keratomileusis, for which approval is anticipated by year-end. The Keracor 116 is indicated for correction of myopia of -1.5 to -7.0 diopters with up to -4.5 D of astigmatism. The device's use "will be limited to the investigational device exemption users originally recruited to perform the clinical studies," B&L says

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel